Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review
- Author(s)
- Anderson, AC; Ho, J; Hall, ET; Hannan, R; Liao, JJ; Louie, AV; Ma, TM; Psutka, SP; Rengan, R; Siva, S; Swaminath, A; Tachiki, L; Tang, C; Teh, BS; Tsai, J; Tykodi, SS; Weg, E; Zaorsky, NG; Lo, SS;
- Journal Title
- Future Oncology
- Publication Type
- Online publication before print
- Abstract
- Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.; [Box: see text].; eng
- Keywords
- Rcc; Sabr; Sbrt; cytoreduction; immunotherapy; metastasis-directed therapy; oligometastatic; oligoprogressive; renal cell carcinoma
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1080/14796694.2024.2389769
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-26 03:27:20
Last Modified: 2024-09-26 03:32:37